Metal Ion Nucleic Acid Aptamer Screening Service

KMD Bioscience, with years of research experience in antibody discovery, focuses on providing customers with efficient, highly specific, and affinity nucleic acid aptamer in vitro screening services. Based on customers’ specific screening targets, we tailor aptamer selex screening solutions and quickly and accurately screen aptamers for the target. KMD Bioscience can provide aptamer selex screening services based on multiple sample types (including proteins, peptides, amino acids, small molecule substances, cells and bacteria, metal ions, etc.), and the services provided to customers cover the upstream and downstream of aptamer selex screening, from gene analysis and synthesis, nucleic acid aptamer sequence design, aptamer in vitro screening, aptamer synthesis, to affinity determination. KMD Bioscience can arrange experiments at every stage according to customer needs. For some metal ions with simple structures and single binding sites, KMD Bioscience uses affinity chromatography SELEX and graphene oxide SELEX screening techniques, carefully planned by a team of scientists to meet the diverse needs of customers.

The nucleic acid aptamer services provided by KMD Bioscience for various types of samples are based on the SELEX screening technology of the SELEX library to screen and obtain corresponding DNA or RNA sequences. Multiple screening methods (including but not limited to cell-SELEX, magnetic bead SELEX, affinity chromatography SELEX, capture SELEX, etc.) are used to meet the screening requirements of different samples. At the same time, KMD Bioscience’s selex library has a capacity of up to 10^13-10^14. After 6-10 rounds of screening and enrichment, it can ensure the acquisition of aptamers targeting the target substance (with binding affinity at the nM pM level), which has greater advantages compared to conventional aptamer screening. The research team of KMD Bioscience lays a solid foundation for the subsequent functional validation of aptamers for customers, including but not limited to affinity validation, competitive ELISA validation, in vitro targeted cell functional validation (such as in vitro recognition and inhibition of nucleic acid aptamers, in vitro flow cytometry blocking function, etc.), and in vivo functional validation (such as in vivo targeted inhibition function validation of aptamers, signal pathway blocking function validation, etc.), providing support for customers’ subsequent research work on targeted molecular drug development.